OA12016A - Tricyclic inhibitors of poly(adp-ribose)polymerases. - Google Patents

Tricyclic inhibitors of poly(adp-ribose)polymerases. Download PDF

Info

Publication number
OA12016A
OA12016A OA1200200064A OA1200200064A OA12016A OA 12016 A OA12016 A OA 12016A OA 1200200064 A OA1200200064 A OA 1200200064A OA 1200200064 A OA1200200064 A OA 1200200064A OA 12016 A OA12016 A OA 12016A
Authority
OA
OAPI
Prior art keywords
aryl
alkynyl
heterocycloalkyl
alkyl
cycloalkyl
Prior art date
Application number
OA1200200064A
Other languages
English (en)
Inventor
Stephen Evan Webber
Donald James Skalitzky
Jayashree Tikhe
Robert Arnold Kumpf
Joseph Timothy Marakovits
Walter Brian Eastman
Original Assignee
Agouron Pharma
Cancer Res Campaign
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agouron Pharma, Cancer Res Campaign filed Critical Agouron Pharma
Publication of OA12016A publication Critical patent/OA12016A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06Peri-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
OA1200200064A 1999-08-31 2000-08-31 Tricyclic inhibitors of poly(adp-ribose)polymerases. OA12016A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15214299P 1999-08-31 1999-08-31

Publications (1)

Publication Number Publication Date
OA12016A true OA12016A (en) 2006-04-19

Family

ID=22541675

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200200064A OA12016A (en) 1999-08-31 2000-08-31 Tricyclic inhibitors of poly(adp-ribose)polymerases.

Country Status (48)

Country Link
US (1) US6548494B1 (https=)
EP (1) EP1208104B1 (https=)
JP (1) JP4272375B2 (https=)
KR (1) KR20020038742A (https=)
CN (1) CN1384835A (https=)
AP (1) AP1553A (https=)
AR (1) AR035162A1 (https=)
AT (1) ATE287406T1 (https=)
AU (1) AU781826B2 (https=)
BG (1) BG106562A (https=)
BR (1) BR0015051A (https=)
CA (1) CA2382404C (https=)
CO (1) CO5200769A1 (https=)
CR (1) CR6577A (https=)
CZ (1) CZ2002613A3 (https=)
DE (1) DE60017575T2 (https=)
DK (1) DK1208104T3 (https=)
DO (1) DOP2000000069A (https=)
DZ (1) DZ3216A1 (https=)
EA (1) EA200200306A1 (https=)
EC (1) ECSP003637A (https=)
EE (1) EE200200100A (https=)
ES (1) ES2234657T3 (https=)
GE (1) GEP20043268B (https=)
GT (1) GT200000145A (https=)
HK (1) HK1045509B (https=)
HR (1) HRP20020271A2 (https=)
HU (1) HUP0202703A3 (https=)
IL (1) IL147863A0 (https=)
IS (1) IS6289A (https=)
MA (1) MA25876A1 (https=)
MX (1) MXPA02002138A (https=)
MY (1) MY135910A (https=)
NO (1) NO322475B1 (https=)
NZ (1) NZ516793A (https=)
OA (1) OA12016A (https=)
PA (1) PA8501801A1 (https=)
PE (1) PE20010538A1 (https=)
PL (1) PL354242A1 (https=)
PT (1) PT1208104E (https=)
SI (1) SI1208104T1 (https=)
SK (1) SK2592002A3 (https=)
SV (1) SV2003000162A (https=)
UA (1) UA73144C2 (https=)
UY (1) UY26323A1 (https=)
WO (1) WO2001016136A2 (https=)
YU (1) YU15102A (https=)
ZA (1) ZA200200830B (https=)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291425B1 (en) 1999-09-01 2001-09-18 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage
DE19946289A1 (de) * 1999-09-28 2001-03-29 Basf Ag Benzodiazepin-Derivate, deren Herstellung und Anwendung
KR20010087401A (ko) * 1999-09-28 2001-09-15 스타르크, 카르크 아제피노인돌 유도체, 그의 제법 및 용도
DE10021468A1 (de) * 2000-05-04 2001-11-08 Basf Ag Verwendung von PARP-Inhibitoren in kosmetischen Zubereitungen
US7151102B2 (en) 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
FR2816942B1 (fr) * 2000-11-23 2003-05-09 Sanofi Synthelabo Derives de benzimidazole, leur preparation et leur application en therapeutique
WO2003051879A1 (en) * 2001-12-14 2003-06-26 Altana Pharma Ag Known and novel 4,5-dihydro-imidazo[4,5,1-ij]quinolin-6-ones useful as poly(adp-ribose)polymerase inhibitors
US7026311B2 (en) 2002-01-10 2006-04-11 Abbott Gmbh & Co., Kg Dibenzodiazepine derivatives, their preparation and use
DE60335359D1 (de) 2002-04-30 2011-01-27 Kudos Pharm Ltd Phthalazinonderivate
AU2003236686A1 (en) * 2002-06-07 2003-12-22 Altana Pharma Ag 4,5-dihydro-imidazo(4,5,1-j) quinolin-6-ones as parp inhibitors
CA2512683C (en) 2003-01-09 2010-03-16 Pfizer Inc. Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
GB0305681D0 (en) 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
SI1660095T1 (sl) 2003-07-25 2010-05-31 Cancer Rec Tech Ltd Triciklični parp inhibitorji
GB0317466D0 (en) * 2003-07-25 2003-08-27 Univ Sheffield Use
WO2005035534A1 (ja) * 2003-10-08 2005-04-21 Ono Pharmaceutical Co., Ltd. 複素ビシクロ環および複素トリシクロ環化合物およびその医薬
KR20060123403A (ko) 2003-12-01 2006-12-01 쿠도스 파마슈티칼스 리미티드 암 치료를 위한 dna 손상 수복 억제제
GB0419072D0 (en) 2004-08-26 2004-09-29 Kudos Pharm Ltd Phthalazinone derivatives
DK1794163T3 (da) * 2004-09-22 2010-04-12 Pfizer Fremgangsmåde til fremstilling af poly(ADP-ribose)polymeraseinhibitorer
WO2006078711A2 (en) * 2005-01-19 2006-07-27 Mgi Gp, Inc. Diazabenzo[de]anthracen-3-one compounds and methods for inhibiting parp
CA2609562A1 (en) 2005-06-14 2006-12-28 Schering Corporation Macrocyclic heterocyclic aspartyl protease inhibitors
US20090226412A1 (en) 2005-06-24 2009-09-10 Ono Pharmaceutical Co., Ltd., Agent for reduction of bleeding in cerebrovascular disorder
CA2615374A1 (en) * 2005-07-18 2007-01-25 Ernest Kun Kun Treatment of cancer
KR20080035576A (ko) * 2005-08-05 2008-04-23 아스트라제네카 아베 트리사이클릭 벤즈이미다졸 및 대사체 글루타메이트 수용체조절제로서 이들의 용도
GB0521373D0 (en) 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
US20080262062A1 (en) * 2006-11-20 2008-10-23 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
WO2008147418A1 (en) * 2006-06-12 2008-12-04 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
US20100279327A1 (en) * 2006-06-12 2010-11-04 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
CA2662337A1 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Inhibition of fatty acid synthesis by parp inhibitors and methods of treatment thereof
JP2010502730A (ja) * 2006-09-05 2010-01-28 バイパー サイエンシズ,インコーポレイティド 癌の治療法
UY30639A1 (es) 2006-10-17 2008-05-31 Kudos Pharm Ltd Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones
AU2008258599B2 (en) 2007-06-05 2013-06-13 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission
WO2008154129A1 (en) * 2007-06-08 2008-12-18 Bausch & Lomb Incorporated Pharmaceutical compositions and method for treating, reducing, ameliorating, alleviating, or preventing dry eye
MX2010002749A (es) 2007-09-14 2010-06-25 Astrazeneca Ab Derivados de ftalazinona.
CN103169973A (zh) * 2007-11-12 2013-06-26 彼帕科学公司 使用4-碘-3-硝基苯甲酰胺化合物与抗肿瘤剂组合治疗乳腺癌
KR20100102607A (ko) * 2007-11-12 2010-09-24 바이파 사이언스 인코포레이티드 Parp 억제제를 단독으로 사용하거나 항종양제와 병용하여 자궁암 및 난소암을 치료하는 방법
CA2708157A1 (en) * 2007-12-07 2009-06-11 Bipar Sciences, Inc. Treatment of cancer with combinations of topoisomerase inhibitors and parp inhibitors
AR070221A1 (es) 2008-01-23 2010-03-25 Astrazeneca Ab Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas.
CA2713156A1 (en) * 2008-02-04 2009-08-13 Bipar Sciences, Inc. Methods of diagnosing and treating parp-mediated diseases
GB0804755D0 (en) * 2008-03-14 2008-04-16 Angeletti P Ist Richerche Bio Therapeutic compounds
ES2598178T5 (es) 2008-10-07 2023-12-26 Kudos Pharm Ltd Formulación farmacéutica 514
WO2011058367A2 (en) 2009-11-13 2011-05-19 Astrazeneca Ab Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor
EP2892344A1 (de) * 2012-09-05 2015-07-15 Bayer CropScience AG Verwendung substituierter benzodiazepinone und benzazepinone oder deren salze als wirkstoffe gegen abiotischen pflanzenstress
CA2935857C (en) * 2014-01-05 2020-12-15 Washington University Radiolabeled tracers for poly (adp-ribose) polymerase-1 (parp-1), methods and uses therefor
JP6457696B2 (ja) 2015-07-23 2019-01-23 アンスティテュ・キュリInstitut Curie 癌を処置するためのDbait分子とPARPインヒビターとの組合せの使用
GB201519573D0 (en) 2015-11-05 2015-12-23 King S College London Combination
US10874641B2 (en) 2016-07-28 2020-12-29 Mitobridge, Inc. Methods of treating acute kidney injury
AU2017355402A1 (en) 2016-11-02 2019-05-30 Health Research, Inc. Combination treatment with antibody-drug conjugates and PARP inhibitors
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
WO2018197461A1 (en) 2017-04-28 2018-11-01 Akribes Biomedical Gmbh A parp inhibitor in combination with a glucocorticoid and/or ascorbic acid and/or a protein growth factor for the treatment of impaired wound healing
KR20200121800A (ko) 2018-01-05 2020-10-26 싸이브렉사 1, 인크. 산성 또는 저산소성 질환에 걸린 조직에 관련된 질환의 치료를 위한 화합물, 조성물 및 방법
KR20200130856A (ko) 2018-03-13 2020-11-20 옹쎄오 암 치료에서 획득한 내성에 대한 디베이트 분자
JP2021530442A (ja) * 2018-06-28 2021-11-11 ジエンス ヘンルイ メデイシンカンパニー リミテッドJiangsu Hengrui Medicine Co., Ltd. 縮合三環系複素環化合物およびその治療上の使用
JP7584802B2 (ja) * 2018-08-24 2024-11-18 アドライ・ノーティ・バイオファーマ・カンパニー・リミテッド 高活性stingタンパク質アゴニスト
WO2020124059A1 (en) * 2018-12-14 2020-06-18 Eternity Bioscience Inc. Tricyclic compounds as sting agonists, and preparation methods and medicinal uses thereof
SG11202108399PA (en) * 2019-02-02 2021-09-29 Chia Tai Tianqing Pharmaceutical Group Co Ltd Indolo heptamyl oxime analogue as parp inhibitor
CN111909157B (zh) * 2019-05-07 2023-02-03 南京药石科技股份有限公司 Ezh2抑制剂及其用途
TW202116356A (zh) 2019-07-10 2021-05-01 美商斯布雷克薩三號公司 作為治療劑之微管靶向藥劑之肽結合物
CN114341162B (zh) 2019-07-10 2025-10-17 赛博克萨2公司 作为治疗剂的细胞毒素的肽缀合物
GB201913030D0 (en) 2019-09-10 2019-10-23 Francis Crick Institute Ltd Treatment of hr deficient cancer
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
EP4143182B1 (en) 2020-04-28 2024-12-11 Rhizen Pharmaceuticals AG Novel compounds useful as poly(adp-ribose) polymerase (parp) inhibitors
WO2022090938A1 (en) 2020-10-31 2022-05-05 Rhizen Pharmaceuticals Ag Phthalazinone derivatives useful as parp inhibitors
US20240093250A1 (en) 2021-01-08 2024-03-21 Cybrexa 2, Inc. Process for preparing a conjugate linking moiety
WO2022155172A1 (en) 2021-01-13 2022-07-21 Cybrexa 3, Inc. Peptide conjugates of therapeutics
IL307339A (en) 2021-04-08 2023-11-01 Rhizen Pharmaceuticals Ag Poly(ADP-ribose) polymerase inhibitors
WO2023154466A1 (en) * 2022-02-11 2023-08-17 The University Of North Carolina At Chapel Hill Arylbenzoisoxazole compounds as ip6k and ipmk inhibitors and methods of use thereof
KR20260030809A (ko) 2023-06-21 2026-03-06 테트라곤 바이오사이언시스 엘티디 Hr 능숙형 암을 치료하는 방법에 사용하기 위한 데옥시시티딘 유도체 및 parp 억제제를 포함하는 조합
WO2025106920A1 (en) * 2023-11-15 2025-05-22 Yale University Parp pet imaging agents and methods of using the same

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1052390A (https=) 1964-03-24
US3642820A (en) * 1969-11-03 1972-02-15 Upjohn Co 4 5-dihydropyrrolo(3 2 1-jk)(1 4)bezodiazepines
US3734919A (en) * 1969-11-03 1973-05-22 Upjohn Co 4,5-di-hydropyrrolo(3,2,1-jk)(1,4)benzodiazepin-7(6h)-ones and 4,5-di-hydropyrrolo(1,2,3-ef)(1,5)benzodiazepin-6(7h)-ones
DE2056215A1 (de) 1970-11-16 1972-05-18 Farbwerke Hoechst AG, vorm. Meister Lucius & Brüning, 6000 Frankfurt Verfahren zur Herstellung von N-Mono-(beta-Cyanäthyl>anilinen
US3883590A (en) 1971-06-01 1975-05-13 Universal Oil Prod Co Preparation of n-alkylarylcarboxamides
US3900477A (en) 1973-11-06 1975-08-19 Ayerst Mckenna & Harrison 5-amino-and 5-hydrazinodihydropyrroloisoquinoline derivatives
US3978066A (en) 1973-11-06 1976-08-31 Ayerst, Mckenna And Harrison Ltd. Certain 4,6-dihydropyrrolotriazoline-quinoline derivatives
US3950343A (en) 1973-11-06 1976-04-13 Ayerst, Mckenna And Harrison Ltd. Pyrroloisoquinoline derivatives
JPS57144286A (en) 1981-03-02 1982-09-06 Takeda Chem Ind Ltd Azepinoindole derivative and its preparation
US4910193A (en) 1985-12-16 1990-03-20 Sandoz Ltd. Treatment of gastrointestinal disorders
DE4125292A1 (de) 1991-07-31 1993-02-04 Kali Chemie Pharma Gmbh 6-oxo-azepinoindol-verbindungen sowie verfahren und zwischenprodukte zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US5342946A (en) 1992-12-02 1994-08-30 Guilford Pharmaceuticals Inc. Phosphonoalkylquinolin-2-ones as novel antagonists of non-NMDA ionotropic excitatory amino acid receptors
WO1995009159A1 (en) 1993-09-28 1995-04-06 Otsuka Pharmaceutical Company, Limited Quinoxaline derivative as antidiabetic agent
US5587384A (en) 1994-02-04 1996-12-24 The Johns Hopkins University Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity
GB9404485D0 (en) 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues
US5561161A (en) 1994-03-25 1996-10-01 Oxigene, Inc. Methods of administering and pharmaceutical formulations containing n-substituted benzamides and/or acid addition salts thereof
US5589483A (en) 1994-12-21 1996-12-31 Geron Corporation Isoquinoline poly (ADP-ribose) polymerase inhibitors to treat skin diseases associated with cellular senescence
ES2105959B1 (es) 1995-01-17 1998-07-01 Zeneca Pharma Sa Derivados de 1,4-dioxido de quinoxalina, procedimiento de preparacion y de utilizacion.
US5659082A (en) 1995-04-03 1997-08-19 Centaur Pharmaceuticals, Inc. Nitro- and aminobenzamide compounds for neurodegenerative disorders
US5756548A (en) 1995-04-03 1998-05-26 Centaur Pharmaceuticals, Inc. Acetamidobenzamide compounds for neurodegenerative disorders
IL123147A (en) 1995-08-02 2004-02-19 Univ Newcastle Ventures Ltd Benzamide imidazole - 4 carboxamide and their use
HUT76302A (en) 1995-11-30 1997-07-28 Chinoin Gyogyszer Es Vegyeszet Quinoxaline derivatives, pharmaceutical compositions containing them and process for producing them
GB9702701D0 (en) 1997-02-01 1997-04-02 Univ Newcastle Ventures Ltd Quinazolinone compounds
AU745790B2 (en) 1997-05-13 2002-03-28 Octamer, Inc. Methods for treating inflammation and inflammatory diseases using pADPRT inhibitors
WO1999011644A1 (en) 1997-09-03 1999-03-11 Guilford Pharmaceuticals Inc. Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity
WO1999011622A1 (en) 1997-09-03 1999-03-11 Guilford Pharmaceuticals Inc. Amino-substituted compounds, methods, and compositions for inhibiting parp activity
US6635642B1 (en) 1997-09-03 2003-10-21 Guilford Pharmaceuticals Inc. PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
US20020028813A1 (en) 1997-09-03 2002-03-07 Paul F. Jackson Thioalkyl compounds, methods, and compositions for inhibiting parp activity
US20020022636A1 (en) 1997-09-03 2002-02-21 Jia-He Li Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity
US6197785B1 (en) 1997-09-03 2001-03-06 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity
US6514983B1 (en) 1997-09-03 2003-02-04 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
JP2002515488A (ja) 1998-05-15 2002-05-28 ギルフォード ファーマシューティカルズ インコーポレイテッド カルボキサミド化合物、組成物、及びparp活性の抑制方法
CA2332239A1 (en) 1998-05-15 1999-11-25 Guilford Pharmaceuticals Inc. Fused tricyclic compounds which inhibit parp activity

Also Published As

Publication number Publication date
ES2234657T3 (es) 2005-07-01
IL147863A0 (en) 2002-08-14
MA25876A1 (fr) 2003-10-01
NZ516793A (en) 2004-03-26
DOP2000000069A (es) 2002-08-30
YU15102A (sh) 2004-12-31
PT1208104E (pt) 2005-04-29
JP2003513015A (ja) 2003-04-08
EP1208104B1 (en) 2005-01-19
PE20010538A1 (es) 2001-05-22
CA2382404C (en) 2009-03-24
BR0015051A (pt) 2002-06-25
NO20020421L (no) 2002-04-25
HUP0202703A2 (hu) 2002-12-28
CO5200769A1 (es) 2002-09-27
KR20020038742A (ko) 2002-05-23
UY26323A1 (es) 2001-04-30
WO2001016136B1 (en) 2001-11-15
AU7338900A (en) 2001-03-26
ATE287406T1 (de) 2005-02-15
GT200000145A (es) 2002-02-21
SK2592002A3 (en) 2002-10-08
NO20020421D0 (no) 2002-01-28
PA8501801A1 (es) 2002-08-26
AR035162A1 (es) 2004-05-05
SV2003000162A (es) 2003-07-29
HK1045509A1 (en) 2002-11-29
EP1208104A2 (en) 2002-05-29
UA73144C2 (en) 2005-06-15
DE60017575T2 (de) 2005-06-09
ECSP003637A (es) 2002-03-25
EE200200100A (et) 2003-06-16
AU781826B2 (en) 2005-06-16
PL354242A1 (en) 2003-12-29
JP4272375B2 (ja) 2009-06-03
HK1045509B (en) 2005-04-29
AP1553A (en) 2006-01-18
MXPA02002138A (es) 2003-08-20
HRP20020271A2 (en) 2005-12-31
US6548494B1 (en) 2003-04-15
WO2001016136A2 (en) 2001-03-08
CN1384835A (zh) 2002-12-11
DK1208104T3 (da) 2005-05-02
IS6289A (is) 2002-02-27
HUP0202703A3 (en) 2004-12-28
CR6577A (es) 2003-12-05
NO322475B1 (no) 2006-10-09
DE60017575D1 (de) 2005-02-24
CA2382404A1 (en) 2001-03-08
ZA200200830B (en) 2003-03-26
SI1208104T1 (en) 2005-06-30
GEP20043268B (en) 2004-06-25
BG106562A (bg) 2003-03-31
MY135910A (en) 2008-07-31
DZ3216A1 (fr) 2001-03-08
EA200200306A1 (ru) 2002-08-29
WO2001016136A3 (en) 2001-06-21
CZ2002613A3 (cs) 2002-08-14

Similar Documents

Publication Publication Date Title
EP1208104B1 (en) Tricyclic inhibitors of poly(adp-ribose) polymerases
AU2004203977B2 (en) Diazepinoindole derivatives as kinase inhibitors
JP5560278B2 (ja) キナーゼ阻害剤として有用なイミダゾピリダジンカルボニトリル
WO2003106430A1 (en) Benzimidazole inhibitors of poly(adp-ribosyl) polymerase
CN115611898A (zh) 四环类衍生物、其制备方法及其在医药上的应用
CN116162099A (zh) 杂环类衍生物及其制备方法和用途
RO121778B1 (ro) Inhibitori triciclici de poli(adp-riboza) polimerază
JP2016537366A (ja) カゼインキナーゼ1d/e阻害剤としての置換された4,5,6,7−テトラヒドロピラゾロ[1,5−a]ピラジン誘導体
EP1937680A2 (en) Novel imidazo [4,5 -b] pyridine derivatives as inhibitors of glycogen synthase kinase 3 for use in the treatment of dementia and neurodegenerative disorders
CN105073751A (zh) 作为酪蛋白激酶1δ/ε抑制剂的新的取代的咪唑
CN116113416B (zh) 四环类衍生物、其制备方法和其医药上的用途
JP2025156455A (ja) チアゾロ[5,4-b]ピリジンMALT-1阻害剤
EP3960736A1 (en) Heterocyclic compound, application thereof, and composition containing same
WO1999040093A2 (en) Synthesis of quinobenzoxazine analogues with topoisomerase ii and quadruplex interactions for use as antineoplastic agents
TW202214634A (zh) 雜環化合物及其衍生物
WO2023015156A1 (en) Pyrrolopyridine-3- and 4-carboxamide compositions and methods for cellular proliferation
KR20230096965A (ko) 아릴아미드 화합물, 이를 포함하는 약학적 조성물, 및 이의 제조방법 및 용도
EP3915990A1 (en) 4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-3,6-dihydropyridine-1-(2h)-carboxamide derivatives as limk and/or rock kinases inhibitors for use in the treatment of cancer
KR20240158251A (ko) 피리도[1,2-a]피리미딘-4-온 유도체
Gam et al. Synthesis of quinobenzoxazine analogues with topoisomerase II and quadruplex interactions for use as antineoplastic agents